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Sepsis is a frequent complication in immunosuppressed cancer patients and
hematopoietic stem cell transplant recipients that is associated with high morbidity
and mortality rates. The worldwide emergence of antimicrobial resistance is of special
concern in this population because any delay in starting adequate empirical antibiotic
therapy can lead to poor outcomes. In this review, we aim to address: (1) the mechanisms
involved in the development of sepsis and septic shock in these patients; (2) the risk
factors associated with a worse prognosis; (3) the impact of adequate initial empirical
antibiotic therapy given the current era of widespread antimicrobial resistance; and (4) the
optimal management of sepsis, including adequate and early source control of infection,
optimized antibiotic use based on the pharmacokinetic and pharmacodynamics changes
in these patients, and the role of the new available antibiotics.
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INTRODUCTION
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response
to infection. It is associated with significant morbidity and mortality (1–3) that increase markedly
when septic shock becomes established. Moreover, sepsis and septic shock are major healthcare
problems, affecting millions of people worldwide each year, with the increasing cost of sepsis-
associated medical care now estimated at $17 billion annually in the United States (4). Given the
rapidly expanding elderly population with their associated immune senescence and frailty (5),
the mortality rates associated with sepsis are expected to increase dramatically over the next 2
decades (6).
The epidemiology of sepsis in industrialized countries is mainly influenced by the age of the
population and the increasing prevalence of comorbidities, such as chronic organ dysfunctions,
non-cancer-related immunosuppressive diseases, or cancer itself. Patients with cancer are at more
than ten times higher risk for sepsis than the general population, with some variability according
to the cancer types (7, 8). Mortality due to sepsis has decreased over time in these patients,
probably due to improvements in the general management of sepsis, advances in cancer therapies,
and improvements in the intensive care unit (ICU) admission policies. Nevertheless, in recent
decades, we are facing the alarming emergence of antimicrobial resistance among microorganisms
that cause infection and sepsis, in both the general population and the immunosuppressed alike,
which can negatively influence outcomes (9). Of special concern is the widespread emergence and
dissemination of multidrug-resistant (MDR) Gram-negative bacilli (GNB), which are a common
cause of infection and sepsis in patients with cancer. Several investigators have reported high rates
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of bacteremia due to extended-spectrum β-lactamase (ESBL)-
producing Enterobacterales (10–13), MDR Pseudomonas
aeruginosa (MDR-PA) (12, 14–17), and carbapenem-resistant
Enterobacterales (CRE) (18–22), among others, against which
there are few treatment alternatives. This is of paramount
importance because inadequate initial empirical antibiotic
therapy can increase mortality when patients with cancer have
infection due to MDR-GNB (11, 13–16, 18–23). Therefore, in
the current era of widespread antibacterial resistance, there
is an urgent need for the development of new agents with
activity against MDR-GNB. In the meantime, novel ß-lactam/ß-
lactamase inhibitors may be safe and effective options for treating
infections due to some of these MDR-GNB (24, 25). In addition,
specific strategies may help improve the overall prognosis
of immunosuppressed patients with cancer, such as rapidly
identifying sepsis (e.g., scores and biomarkers), optimizing
ß-lactam antibiotic use (e.g., extended infusions), and optimizing
source control and providing aggressive management in the ICU.
Finally, the pathophysiology of sepsis in the presence
of cancer is especially complex because both entities share
pathophysiological characteristics that result from the incapacity
of the host’s immune system to deal with an initial trigger.
Thus, a dysregulated immune system seems common to both
scenarios, raising the specter of their mutual impact on each
other’s course. Improving our knowledge about this bidirectional
interaction between sepsis and cancer may lead to future research
possibilities that could help modulate the dysfunctional immune
system and the hyperinflammatory state, thereby improving
sepsis control.
In this review, we aim to assess the prevalence, characteristics,
etiology, and outcomes of sepsis in immunocompromised
cancer patients and hematopoietic stem cell transplant (HSCT)
recipients and to gain knowledge regarding the physiopathology
of sepsis in these contexts. We also aim to review optimal
management in the current era of widespread antimicrobial
resistance. Finally, we will briefly comment on the current gaps in
the literature and on directions for future research. Our focus is
on sepsis due to bacterial infection. This review was not designed
to provide evidence-qualified recommendations.
SEARCH STRATEGY AND SELECTION
CRITERIA
We searched PubMed/MEDLINE for articles that were published
from January 2000 to October 2020, using the following terms:
“sepsis,” “severe sepsis,” “septic shock,” “pathophysiology,”
“immunosuppression,” “cancer,” “solid tumor,” “hematologic
malignancy,” “hematopoietic stem cell transplant,” “neutropenia,”
“bacteremia,” “bloodstream infection,” “intensive care unit,”
“antibiotic resistance,” “multidrug resistance,” “mortality,”
“SOFA,” “procalcitonin,” “C-reactive protein,” “adrenomedullin,”
“ceftolozane/tazobactam,” “ceftazidime/avibactam,” and
“extended infusion.” Articles resulting from these searches,
together with any relevant references cited in those articles,
were reviewed. We only included articles written in English and
involving adult patients.
THE BURDEN OF SEPSIS IN CANCER
PATIENTS
Some years ago, Angus et al. reported that one in 6 patients with
sepsis presented a malignant underlying disease and that these
patients suffered 30% excess mortality than other patients with
sepsis (26). More recent ICU observational series have confirmed
that about 15–20% of patients admitted to critical units have
hematologic or solid malignancies (27–30), with sepsis being
a leading cause of ICU admission in these patients (31, 32).
Nevertheless, sepsis-associated mortality in cancer patients has
decreased over recent decades (33–36), probably due to advances
in sepsis diagnosis and management, cancer therapies, and ICU
admission policies (37–39).
The current rates of in-hospital mortality of cancer patients
presenting with sepsis and septic shock are ∼20 and 40%,
respectively (36). Sepsis-related mortality relies on not only
appropriate early management of multiple organ failure but also
minimizing prolonged ICU stays and associated complications
(40, 41). Moreover, the long-term outcome of cancer sepsis
survivors after ICU admission is depended on the prognostic
determinants of the underlying diseases as well as the possibility
of continuing antineoplastic treatment, which may be hampered
by loss of functional status and/or persistent organ dysfunction
(42–45). Importantly, since early sepsis mortality has decreased
over time, attention has recently been paid to late mortality
after recovery from sepsis. Even though the exact causes of
long-term sepsis mortality are still unclear, some investigations
suggest that older age, comorbidities, and persistent organ injury
are detrimental and lead to the immune system’s dysfunction
and suppression, with persistent inflammation and catabolism
(46, 47).
The increased risk of sepsis in cancer patients is due to
several factors: immunosuppression caused by the underlying
disease, the specific onco-hematological treatments causing
immunosuppression, and the invasive procedures used (e.g.,
long-term central venous catheters, urinary catheters, drainages,
etc.). However, the cancer population is heterogeneous and
there is great variation in the degree of immunosuppression.
Hematological patients are at highest risk of infection and
sepsis, particularly those with acute leukemia who often present
prolonged and profound neutropenia (36, 48, 49), historically
one of the most important risk factors for sepsis and mortality
(50, 51).
Multiple myeloma and HSCT also place patients at higher
risk of sepsis compared with other hematological malignancies
(36, 40). HSCT recipients represent a unique population
that is severely immunosuppressed due to the underlying
disorder, the conditioning regimen, and the treatment of
complications, such as graft-vs. host-disease (GVHD). In
this setting, allogeneic transplant recipients presenting with
GVHD seem to be at higher risk of sepsis and death
compared to non-HSCT recipients and both autologous
and allogeneic patients without GVHD, reaching mortality
rates as high as 55% (52). Among patients with solid
tumors, the most sepsis occurs with lung or gastrointestinal
cancers, followed by other subtypes depending on the series.
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In patients with solid malignancies, the site of primary
or metastatic tumor often serves as the portal of entry
(36, 48, 53, 54).
Even though febrile neutropenia (FN) is a frequent
complication, occurring in 20–30% of patients with solid
tumors and 80% of patients with hematological malignancies
receiving chemotherapy, only 20–30% will develop bacteremia.
Therefore, the rate of sepsis and septic shock globally is relatively
low for FN. In line with this, a recent Brazilian study evaluating
the frequency and epidemiology of early death and shock in
1,305 episodes of FN in 826 hematologic patients collected from
2003 to 2017 found that shock occurred in 42 (3.2%) on the first
day of FN and early death occurred in 1.1% (55). In this study,
predictors of septic shock were bacteremia due to Escherichia
coli [odds ratio (OR), 8.47; 95% CI 4.08–17.55; p < 0.001),
Enterobacter sp. (OR, 7.53; 95% CI 1.60–35.33; p = 0.01), and
Acinetobacter sp. (OR, 6.95; 95% CI 1.49–32.36; p= 0.01).
PATHOPHYSIOLOGY OF SEPSIS IN
CANCER PATIENTS
Sepsis-Related Immunosuppression
Sepsis is an extremely complicated process in which several
situationsmay occur and lead to a persistent immunosuppression
and hyperinflammation. On the one hand, it induces a severe
state of immunosuppression that affects both cellular effectors
of the innate and adaptative immune systems, changes that
can persist even after recovery (56, 57). These comprise
functionally essential cells, such as neutrophils, monocytes
and macrophages, natural killer (NK) cells, dendritic cells, B
lymphocytes, and T lymphocytes (including gamma delta T cells,
TH cell subpopulations and regulatory T cells). On the other
hand, sepsis induces a state of complex immune dysfunction,
including hyperinflammation (excessive release of inflammatory
cytokines IL-1, TNF, and IL-7) (58), homeostatic dysfunction
(59), complement activation, fibrinolytic and clotting system
stimulation (60), redox imbalance (causing severe oxidative
stress) (61), mitochondrial dysfunction (62), and molecular
alterations (causing organ damage) (56).
Cancer-Related Immunosuppression
The immunosuppression in cancer that increases the risk
of infection and sepsis is mainly associated with specific
onco-hematological therapies that impair the immune system.
Treatment with chemotherapy and radiotherapy alters the
phagocytic activity of neutrophils and monocytes by depleting
their circulating counts and impairing their capacity for
chemotaxis and phagocytosis (63). As mentioned above,
the risk of infection and sepsis is strongly associated with
the depth and duration of neutropenia and monocytopenia
(51, 52). Most cytostatics induce quantitative and/or functional
modifications in lymphocytes and NK cells, while other
anti-lymphoproliferative drugs and monoclonal antibodies
(e.g., fludarabine, bendamustine, ibrutinib, rituximab, and
alemtuzumab) can induce prolonged B- and/or T-cell
lymphopenia (64). Corticosteroid use is also frequent in
cancer patients, increasing the degree of immunosuppression.
They cause both a pleiotropic dysregulation of innate and
adaptive immune responses and a decrease in the activities
of neutrophils, monocytes, macrophages, and lymphocytes
(mainly CD4+ T cells). At high doses, they also induce apoptosis,
decrease IL-2 levels, and impair the Th2-cell response. Therapy
with HSCT may delay immune reconstitution due to persistent
lymphopenia, low cell diversity, and defective lymphocyte
functions (65). In addition, chemotherapy and radiotherapy may
impair other organ and tissue functions, limiting their capacity
to deal with the initial aggression. In this regard, it has been
suggested that the endothelial toxicity secondary to cytostatic
agents may lead to microcirculatory alterations and an impaired
vessel response to vasopressors (66).
There are specific cancer settings that may increase the risk
of infection and sepsis, regardless of antineoplastic therapy.
The involvement of the bone marrow and/or the presence of
dysmyelopoiesis by certain hematological malignancies or by
metastatic solid tumors may lead to important cytopenias and/or
defective phagocytic activity of neutrophils and monocytes
(67). Some lymphoproliferative disorders may also cause
hypogammaglobulinemia, and the compression of anatomic
structures and/or tissue infiltration by malignant cells can
diminish local defense mechanisms.
Finally, tumor cells can escape cytotoxic cells by losing major
histocompatibility class-1 molecules, leading to the inappropriate
expression of checkpoint inhibitory molecules, and can exhibit
functional defects that result in decreased antigen presentation,
and altered dendritic, macrophage, NK, and CD8T cell function
(68). Whether tumor-related immune alterations increase the
risk of infection still needs to be confirmed.
The Bidirectional Interaction Between
Cancer and Sepsis
There are pathophysiological similarities between cancer and
sepsis that favor the interaction between these two processes.
Indeed, some malignancy-related conditions and adverse drug
reactions can mimic sepsis (69) and may hinder differentiation
between these entities. In particular, certain aggressive
hematological diseases, such as acute leukemia and high-
grade B-cell lymphoma may present multiple organ dysfunctions
through several pathways, such as tissue infiltration by tumor
cells, anatomical compression, intracellular metabolite release,
altered coagulation, and hemophagocytic lymphohistiocytosis
(70, 71). Currently available antineoplastic therapies, including
T-cell based therapies (e.g., bispecific monoclonal antibodies
and chimeric antigen receptor-T cells) or differentiating agents
(e.g., all-trans retinoic arsenic or acid), may also produce acute
systemic inflammatory syndromes that mimic sepsis (72, 73).
Differentiating these entities is of paramount importance because
managing these proinflammatory conditions varies significantly.
The similarities between cancer-related and sepsis-induced
immune dysfunctions indicate that immune defects derived
from infectious triggers may facilitate a favorable environment
and promote tumor growth. Consistent epidemiological and
experimental findings support a link between sepsis and further
risk of cancer (74–77). Conversely, some historical reports and
experimental studies have suggested that sepsis may instead have
antitumoral activity (78, 79), with “cancer-then-sepsis” models
suggesting that sepsis may induce tumor suppression (80–82).
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Interestingly, recent data also suggest that antibiotic-induced
dysbiosis (changes in the composition and diversity of gut
microbiota) may alter the immune response to cancer (83, 84).
Finally, it has been hypothesized that certain Toll-like receptors
could have a role in modulating tumor growth in sepsis (85, 86).
CHARACTERISTICS, ETIOLOGY, AND
OUTCOMES OF SEPSIS IN CANCER
PATIENTS
There are several current studies evaluating the prevalence,
clinical features, etiology, and outcomes of cancer patients with
bacteremia, with reported rates of septic shock varying by
series from 6 to 57% (11, 13, 15, 18–20). Nevertheless, very
few investigations have focused on patients presenting with
sepsis or septic shock (31, 36, 48, 49, 52, 55, 87, 88), and
among these, some were retrospective, some used different sepsis
definitions, and some did not provide comprehensive data.
Table 1 summarizes the most relevant data for cancer patients
with sepsis or septic shock.
Overall, patients with hematological malignancies, mainly
acute leukemia, are at greatest risk of sepsis (36, 48, 49).
Patients with multiple myeloma (36, 48, 87) and non-Hodgkin
lymphoma (31, 36, 55, 87) also seem to experience high
rates of sepsis and septic shock. HSCT recipients have been
included in only few series, but rates of sepsis range from
3 (87) to 12% (36), as reported in a recent large study of
cancer with 2,062 patients admitted to seven European ICUs
for sepsis or septic shock. In this study, data were extracted
from the Groupe de Recherche Respiratoire en Réanimation Onco-
Hématologique database, from 2006 to 2010. Patients more often
had hematological (82.4%) than solid (17.6%) malignancies, and
many (31%) had neutropenia at ICU admission. The 30-day
mortality rate was 39.9% and decreased significantly over the
study period [odds ratio (OR) 0.96; 95%CI, 0.93–0.98; p= 0.001].
Seeking to characterize the frequency and outcomes of sepsis
in adult HSCT recipients and to compare them to non-transplant
patients, Kumar et al. retrospectively analyzed a large nationwide
administrative database from almost 20% of the community
hospitals in the United States (52). Data were provided separately
according to the reason for admission (engraftment admission
or subsequent admission with and without GVHD). Of the
291,179 discharges with HSCT between 2000 and 2008, sepsis
was identified in 21,898 (7.5%). The frequency of sepsis was
5 times higher in HSCT recipients than in non-transplant
patients. Allogeneic transplant recipients and those with GVHD
(10.4%) had significantly higher rates of sepsis than either
autologous recipients (13.2 vs. 5.2%; p < 0.001) or those without
GVHD (10.4 vs. 6.1%; p < 0.001). The unadjusted hospital-
related mortality was significantly higher among allogeneic
transplant recipients than non-HSCT recipients (55.1 vs. 32.9%,
p < 0.001), but the mortality rates did not differ between
autologous HSCT recipients and the non-transplant population.
After adjustment, however, the odds of mortality were 3.81
times higher in allogeneic HSCT recipients (95% CI, 2.39–6.07)
and 1.28 times higher in autologous recipients compared with
non-transplant patients (95% CI, 1.06–1.53). Table 2 displays
more detailed information on the engraftment admissions and
compares patients according to the type of transplant.
Among solid tumors, the rates of sepsis vary by the series,
with gastrointestinal (31, 87) and lung cancers (48) being most
susceptible. In a recent report of 1,009 patients with gynecological
cancers receiving 10.239 cycles of chemotherapy, the incidence of
septic shock during neutropenia was 3% and the mortality rate
was 1.2% (88). The incidence of septic shock during neutropenia
was also higher in patients older than 50 years (3.9 vs. 1.4%,
p = 0.034), with a linear-by-linear association between the
accumulated cycles of chemotherapy and the sepsis rate (p =
0.004). Also, patients who had received two or more courses of
chemotherapy presented and increased incidence of neutropenic
septic shock (NSS) compared with those receiving only one
course (4.9 vs. 1.4%, p = 0.002). No significant differences were
observed regarding the type of gynecological cancers and the
status of the disease between patients with NSS and patients
without NSS. The mortality rate of patients with NSS was 37.5%.
In this study, the median age (64.0 vs. 56.5, p = 0.017) and
the peak heart rate (149.5 vs. 123.5 min−1, p = 0.015) were
significantly higher in the group of patients who subsequently
died of NSS than in those who survived.
In∼30–50% of the sepsis and septic shock episodes occurring
in patients with cancer, no microbiological diagnosis is achieved
(31, 87). When a definitive microbiological diagnosis is made,
blood cultures are the most useful tool because most episodes
are secondary to bacteremia and/or high-inoculum infections,
such as pneumonia, with frequent secondary dissemination to
the bloodstream.
The site of infection is barely provided in the few series
addressing sepsis in cancer patients. In a report addressing
shock and early death in hematologic patients with FN, Rosolem
et al. described the site of infection in 563 cases of sepsis
(91% with septic shock) admitted in the ICU (31). The most
frequent sites were the lung (44%), the abdomen (31%), and
the urinary tract (8%), with 24 patients (4%) having more
than one site. GNB were responsible for more than 50% of
episodes, with E. coli (16%), P. aeruginosa (13%), and Klebsiella
pneumoniae (13%) being most common. The overall ICU and
hospital-related mortality were 51 and 65%, respectively; these
were higher in patients with septic shock (62 and 74%) than
in patients with either sepsis (36 and 55%) or sepsis (15 and
25%). Mortality rates were higher for patients with pneumonia
and bacteremia than with gastrointestinal and urinary tract
infections. End-of-life decisions were made for 29% of patients
in their cohort.
In a subgroup analysis of a multicenter prospective cohort
study in 28 Brazilian ICUs, 717 patients with cancer were
analyzed (87). Among them, 37% had sepsis and 53% septic
shock. The most frequent infection sites were the lungs
(48%), abdomen (19%), bloodstream (primary) (19%), and
urinary tract (17%). Half had a microbiologically confirmed
infection, with GNB again being the most frequent cause
(31%). ICU- and hospital-related mortality rates were 42 and
56%, respectively. End-of-life decisions were made in 17% of
the patients.
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TABLE 1 | Summary of the most relevant series of cancer patients presenting with sepsis and septic shock.
Study Rosolem et al. (31) Torres et al. (87) Lemiale et al. (36) cKumar et al. (52)
Study design Secondary analysis of a
prospective cohort
study






patients from 1994 to
2015
Analysis of the healthcare cost and utilization
project-nationwide inpatient sample (NIS) database
Site 10-bed
medical-surgical
cancer ICU unit at
Instituto Nacional de
Cancer, Rio de Janeiro,
Brazil
28 Brazilian ICUs Seven European ICUs
from France and
Belgium
The database contains data from ∼1,000 (20%)
community U.S. hospitals










sepsis or septic shock
6.168 engraftment admissions in HSCT recipients with
sepsis among 79.287 discharges (7.7%)
2.750 admissions for sepsis
in autologous HSCT
recipients (5.2%)
3418 admissions for sepsis
in allogeneic HSCT
recipients (13.2%)
Age (y) 59.2 ± 17.8 63.1 ± 15.0 59 (48–67) 21.6% (≥65 y) 4.35% (≥65 y)
Male sex 301 (54%) 126 (47%) 1.275 (61.8%) 56.6% 6.34%
Hematologic disease 127 (23%) 35 (13%) 1.700 (82.4%) 100% 100%
- NHL 14% 4% 461 (22.4%) 7.8% 3.2%
- Leukemia 6% 4% 591 (28.7% 16.9% 62.5%
- Multiple myeloma 2% 3% 244 (11.8%) 37% 4.5%
- Hodgkin
lymphoma
– – – 10.4% 1.8%
HSCT recipients – 8 (3%) 250 (14%)a 100% 100%
- Solid tumor 436 (77%) 233 (87%) 362 (17.6%) – –
- Gastrointestinal 35% 25% 61 (16.9%) – –
- Head and neck 13% 7% 4 (0.1%) – –
- Lung cancer 6% 9% 48 (13.3%) – –
- Urogenital 6% 15% 43 (11.8%) – –
- Breast 5% 6% 55 (15.2%) – –
- Uterus – – 15 (4.1%) – –
Recurrence/progression 103 18% 35% – – –
PS >2 294 52% 57% – – –
Neutropenia
(<500/mm3 )
71 13% 12% 640 (31%) – –
Comorbidities 349 (62%) – 1.043 (50.6%) – –
- Diabetes mellitus 14% – 6.8% 4.1%
- Hypertension 38% – – –
- COPD 12% – 11.8% 8.2%
Previous chemotherapy
and/or radiotherapy




227 40% 32% – – –
- Nosocomial 336 60% 67.5% – – –
SOFA score (points) on
the first day of ICU
8 (5–11) 9 (7–12) 6 (4–9) – –
Acute organ failures (n) 2 (1–3) 4 (3–4) – 18% (≥3) 24.5% (≥3)
Mechanical ventilation 489 (87%) 51% 1.016 (49.3%) 30.9% 40.4%
Renal replacement
therapy
110 (20%) 18% 420 (20.4%) 11.4% 19.3%
Vasopressor use 372 (64%) 59% 1.172 (56.8%) – –
(Continued)
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TABLE 1 | Continued




180 (32%) 133 (50%) – – –
- Microbiologically
proven
383 (68%) 135 (50.3%)
Severity
- Sepsis 48 (9%) – – – –
- Severe sepsis 143 (25%) 142 (53%) – – –
- Septic shock 372 (66%) 126 (47%) – – –
Pathogens
Gram-positive 168 (30%) 34 (13%) – 33% 38.3%
- Enterococci 92 (16%) – – – –
- S. aureus 61 (11%) 22 (8.2%) – – –
- Group D
streptococci
16 (3%) – – – –
- S. pneumoniae 13 (2%) 4 (1%) – – –
- Other 12 (3%) – – – –
- CNS 297 53%) 13 (5%) – – –
Gram-negative 91 16% 83 (31%) – 16% 15.8%
- Escherichia coli 74 13% 27 (10%) – – –
- P. aeruginosa 72 13% 29 (11%) – – –
- K. pneumoniae 46 8% 27 (10%) – – –
- Enterobacter spp 34 6% – – – –
- Proteus spp 18 4% – – – –
- M. morganii 14 3% – – – –
- S. maltophilia 92 16% 3 (1%) – – –
- Other 43 8% 8 (2.9%) – – –
Fungi – – –
- Candida spp 35 6% 12 (4%) – 3.3% 5.4%
- Other 8 1% 1 (1%) – 2.2%d 5.8%d
Other infectious agents 19 (3%) 39 (15%) – 12%e 13.4%e
Multidrug-resistant
bacteria
81 14% – – − –
Site of infection
Lung 246 44% 130 (48%) – – –
Abdomen 172 31% 67 (25%) – – –
Urinary tract 42 8% 45 (17%) – – –
Skin/soft tissue 35 6% 26 (10%) – – –
Primary bacteremia 24 4% 51 (19%) – – –
Central nervous
system
11 2% 3 (1%) – – –
Surgical site
infection
– 18 (7%) – – –
Other/unknown 57 10% 18 (7%) – – –
More than 1 site of
infection
24 4% 71 (26%) – – –
ICU LOS 9 (4–18) 7 (4–16) – – –
Hospital LOS (days) 23 (11–43) 22 (13–38) – 26 (21–37) 39 (30–58)
ICU mortality 289 51% 42% – – –
In-hospital mortality 364 65% 56% 823 (39.9%)b 30.1% 55.1%
NHL, Non-Hodgkin lymphoma; HSCT, hematopoietic stem cell transplant; COPD, chronic obstructive pulmonary disease; SOFA, Sequential Organ Failure Assessment; ICU, Intensive
care unit; CNS, Coagulase-negative staphylococci; LOS, Length of hospital stay; GRRR-OH, Groupe de Recherché Respiratoire en Réanimation Onco-Hématologique.
aOnly data on allogeneic HSCT were provided; bData on 30-day mortality were available in 943 patients (45.7%), approximated using hospital mortality in 879 patients (42.6%) and as
last resort ICU mortality if the former were unavailable; cOnly data regarding engraftment admission are provided in this table. Data on subsequent admissions in HSCT recipients with
and without graft-vs. host diseases are provided in the complete version of the manuscript. d Infections due to Aspergillus spp.; eClostridioides difficile colitis.
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TABLE 2 | Risk factors associated with mortality in the most relevant series of sepsis and septic shock in cancer patients.
References Patients studied Outcome OR (95% CI) P
Rosolem et al. (31) 563 cancer patients with sepsis In-hospital mortality Admission to a medical ICU 2.19 (1.40–3.42) 0.001
Active-newly diagnosed disease 1.76 (1.12–2.75) 0.013
Active-recurrence/progression 2.42 (1.35–4.35) 0.003
Performance status >2 3.57 (2.36–5.979) <0.001
Non urinary tract infection 3.28 (1.57–6.86) 0.002
SIRS criteria ≥ 3 1.80 (1.20–2.72) 0.014
Cardiovascular dysfunction 1.94 (1.27–2.94) 0.008
Respiratory dysfunction 2.29 (1.24–4.23) 0.002
Renal dysfunction 2.12 (1.34–3.35) 0.001
Torres et al. (87) 268 cancer patients with sepsis In-hospital mortality Organ dysfunction 1.48 (1.16–1.87) 0.001
Hematological malignancy 2.57 (1.05–6.27) 0.038
Performance status >2 2.53 (1.44–4.43) 0.001
Polymicrobial infections 3.74 (1.52–9.21) 0.004
Lemiale et al. (36) 2.062 cancer patients with
sepsis or septic shock
30-day mortality Mechanical ventilation 3.25 (2.52–4.19) <0.01
Vasopressor use 1.42 (1.10–1.83) <0.01
aKumar et al. (52) 6.168 engraftment admissions in
HSCT recipients with sepsis
Unadjusted in-hospital
mortality
Allogeneic HSCT 2.12 (1.55–2.90) NA
Age 35–49 years 1.68 (1.08–2.60) NA
Age ≥65 years 2.08 (1.13–3.83) NA
Cirrhosis as comorbidity 4.49 (1.81–11.1) NA
Multiple myeloma 0.59 (0.40–0.89) NA
Respiratory failure 12.1 (8.64–16.8) NA
Cardiac failure 2.42 (1.59–3.66) NA
Renal failure 2.64 (1.95–3.56) NA
Metabolic failure 1.63 (1.07–2.49) NA
Hepatic failure 5.22 (2.29–11.8) NA
aOnly data regarding engraftment admission are provided in this table. Data on subsequent admissions in HSCT recipients with and without graft-vs. host diseases are provided in the
complete version of the manuscript.
RISK FACTORS FOR MORTALITY IN
CANCER PATIENTS WITH SEPSIS AND
SEPTIC SHOCK
Table 2 shows the risk factors associated with mortality for the
most relevant series of patients with cancer who developed sepsis
or septic shock. The most commonly variables associated with
mortality are those related to the underlying disease (mainly
hematological malignancies) (52, 87) and its status (uncontrolled
cancer and poor performance status) (31, 87), the presence of one
or more organ dysfunctions (31, 52, 87), and the need for organ
support (36). Some other variables identified as risk factors for
mortality include older age (52, 88), comorbidities (52), infection
site (particularly pneumonia) (31), polymicrobial infection (87).
Of note, the year of ICU admission has also been shown to
influence cancer patient’s outcomes significantly, with decreased
mortality rates observed over time (36, 52). The nutritional
status of cancer patients may also play an important role in the
development of sepsis and on its outcomes. In this regard, a study
conducted in our institution involving head and neck cancer
patients (who are particularly malnourished) with bacteremia
identified hypoalbuminemia as independent risk factor for
bacteremia and for early and overall mortality (89). Importantly,
inadequate initial empirical antibiotic therapy (IEAT) is widely
recognized as an important risk factor for mortality in all
patients, including those with immunosuppression due to cancer
(14, 18, 23, 90–92). Kadri et al. recently published a retrospective
cohort analysis of electronic health record data from 131
hospitals in the US that included 21,608 patients with bacteremia
who received empirical antibiotics between 2005 and 2014
(93). Among them, 4,165 (19%) received IEAT, which was
independently associated with increased mortality (adjusted OR
1.46; 95% CI, 1.28–1.66); p < 0.0001), regardless of whether
sepsis or septic shock was present. Infection due to antibiotic-
resistant organisms was strongly associated with an increased risk
of receiving IEAT (adjusted OR 9.09; 95% CI 7.68–10.76; p <
0.0001).
Several studies have shown that cancer patients with infections
due to resistant pathogens are more likely to receive IEAT
(90–92). In addition, many of these studies have shown that
failure to cover resistant organisms, and particularly MDR-GNB,
significantly and independently impairs their outcomes (10, 11,
14, 18, 20, 22, 23). The presence of septic shock and/or the
need for ICU admission have also frequently been identified
as risk factors for mortality in cancer patients with bacteremia
(94). Therefore, it is reasonable to hypothesize that these factors
(IEAT and sepsis/septic shock) synergize to affect the prognosis
of these patients negatively. However, there remains no firm
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evidence of how IEAT impairs outcomes in cancer patients
with sepsis.
OPTIMAL MANAGEMENT OF SEPSIS IN
CANCER PATIENTS
Early Recognition and Diagnosis
In 2017, Rhodes et al. published the “Surviving Sepsis Campaign,”
which are international guidelines for the management of adult
patients with sepsis and septic shock. These guidelines provide
the best evidence-based recommendations for the management
of this life-threatening condition (95).
Several studies in the general population have demonstrated
that the Sequential Organ Failure Assessment (SOFA) score
better predicts hospital mortality for ICU patients with infection
compared with the systemic inflammatory response syndrome.
Therefore, a new definition of sepsis and septic shock was
adopted in 2016 (1), and later studies have demonstrated that the
new definitions are applicable to cancer with the same reliability
as in the general population (94). In addition, the quickSOFA
(qSOFA), constitutes a simple bedside clinical score that can be
rapidly applied and allows the prompt identification of patients
at greatest risk of need for admission to an intensive care unit.
The qSOFA score is based in 3 simple variables, which include
respiratory rate≥22/min, alteration in mental status, and systolic
blood pressure ≤100mm Hg (96). The SOFA and qSOFA scores
are therefore useful tools to identify and predict complications
and mortality in these patients (97–99), and as such, should be
applied to all cancer patients with suspected infection.
In recent decades, over 180 biomarkers have been evaluated
as unsuitable for the diagnosis and prognosis of sepsis, being
lactate one of the most frequently used (100). To date, none have
demonstrated sufficient specificity or sensitivity for reasonable
utility in clinical practice. Procalcitonin (PCT) and C-reactive
protein (CRP) have perhaps been the most widely used, but they
have limited ability to distinguish sepsis from other inflammatory
conditions or to predict outcomes. More recently, elevated serum
lactate has been used as a biomarker in the diagnosis of septic
shock (1). There is also interest in the role of these biomarkers as
diagnostic, prognostic, and theragnostic markers in febrile cancer
patients, particularly those with FN. Despite the paucity of data
about biomarkers in cancer patients, some reports have evaluated
their role. In this regard, PCT has been shown to have better
accuracy than CRP and IL-6 in differentiating infectious from
non-infectious causes of fever in a meta-analysis of 27 studies
in adult and pediatric cohorts (101). However, this meta-analysis
included different types of underlying disease and evaluated
different outcomes. Several other reports have shown that PCT
can predict bacteremia in cancer patients with and without
neutropenia, particularly those with infection by GNB, and that
it may predict a need for organ support (102–106).
Adrenomedullin (ADM) is also elevated in sepsis, which
results in pro-ADM that is present at higher levels in patients
with localized infections and bacteremia than in healthy controls
(107). Pro-ADM has shown to be more suggestive of sepsis than
PCT in cancer patients (108), and its levels are more significantly
elevated in patients with hematological cancers and localized
infections than in those with no infections (108). Nevertheless,
another study of critically ill cancer patient revealed that pro-
ADM and PCT had similar areas under the roc curve for
identifying bacteremia, both being superior to that of CRP (109).
Other biomarkers, such as presepsin, IL-6, and IL-8, appear to be
less useful (110). The role the currently available biomarkers in
cancer patients with sepsis clearly needs to be elucidated further.
Antibiotic Therapy
In the current era of growing antimicrobial resistance, the
following general considerations need to be assessed before
deciding on empirical antibiotic therapy in cancer patients
(particularly in FN): prior history of colonization/infection
with resistant pathogens; the presence of other risk factors
for antibiotic resistance; the local epidemiology and resistance
patterns in that hospital, unit, and geographical area; and
other patient-related factors that may predict a complicated
clinical course (e.g., older age, comorbidities, localized infection,
and shock).
After this evaluation, cancer patients with sepsis or septic
shock need urgent therapy with a broad-spectrum anti-
pseudomonal BLA with or without other agents that are active
both against the suspected organisms and at the site of infection
(111). It remains controversial whether adding a short-course
aminoglycoside to a broad-spectrum BLA regimen can benefit
severely ill patients. An important meta-analysis (112), as well
as a recent prospective observational cohort study of 648 ICU
patients (113), failed to show this association. In the study
by Ong et al. there was no association with a faster reversal
of shock or an increased 14-day survival; however, that study
mainly included immunocompetent patients, and only 4%
received IEAT, probably due to low local levels of antibiotic
resistance (113).
Interestingly, in a previously published study we observed
improved early (7- and 14-day) mortality rates in those
who received initial combination therapy, who also presented
more frequently with septic shock. In a prospective study of
510 hospitalized patients with bacteremia in the context of
neutropenia due to hematological malignancy, we also observed
better 30-day survival in those who received combination
therapy (94). Similar findings have been reported in the
general population by other investigators (114, 115). Therefore,
while awaiting the results of well-designed randomized clinical
trials, we advocate the inclusion of short-course aminoglycoside
therapy with a BLA for IEAT when treating neutropenic cancer
patients in centers with a high prevalence of multidrug resistance,
especially if sepsis or septic shock are present.
The empirical use of the two novel antibiotics,
ceftolozane/tazobactam and ceftazidime/avibactam, should
be considered in cancer patients at risk of infection due to
MDR-GNB (e.g., MDR-PA, CRE, or ESBL-Enterobacterales),
particularly if they present with sepsis or septic shock. Targeted
therapy with these agents should be also considered if other
first-line antibiotics are not viable treatment options because of
a lack of activity or a high-risk of toxicity. Although these novel
antibiotics have not been specifically approved for neutropenic
and/or cancer patients, they are being used in these setting due
to the increasing problem of antibacterial resistance among
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GNB. These drugs have been used in real-world settings, where
they are reported to show clinical and microbiological success in
high-risk hematological patients. However, there is a scarcity of
data, and where it is present, it is based mainly on case series and
case reports (116–122). Table 3 summarizes the main clinical
and microbiological data in these studies.
An alternative strategy for the treatment of infections due to
resistant GNB organisms is to use existing BLAs by extended
or continuous infusion to maximize their pharmacokinetic
(PK) activity (123). Critically ill patients present certain
physiopathologic changes, mainly due to an increased volume
of distribution and an increased renal clearance, making them
excellent targets for this strategy. In fact, two meta-analyses
have shown an association between prolonged BLA infusions
and lower mortality rates in critically ill patients (124, 125).
Cancer patients with FN may be considered similar to critically
ill patients in terms of the intra- and inter-individual variability
of PK parameters (126–128).
Regarding the clinical impact of optimizing the use of BLAs,
data are limited for neutropenic patients and restricted to certain
antibiotics (129, 130). A recent single-center randomized clinical
trial found that extended infusion with a BLAwas associated with
superior outcomes than intermittent infusion, the greatest benefit
observable in patients with pneumonia (131). Nevertheless, that
study had some methodological limitations, and there were no
PK studies to support the clinical results (132). Currently, a
multicenter, open label, randomized, superiority clinical trial is
being performed (EudraCT 2018-001476-37, ClinicalTrials.gov:
NCT04233996) to assess the clinical efficacy of extended
BLA infusions in hematological patients with neutropenia.
Other secondary outcomes include PK/pharmacodynamic target
achievement, bacteremia clearance, CRP decrease, overall 30-day
case-fatality rate, and adverse events. Finally, a population PK
model of the BLA studied will be developed (133).
In the current era of emerging antimicrobial resistance,
antimicrobial stewardship is of paramount importance in order
to decrease the overall antimicrobial consumption and hinder
resistance dissemination. In this regard, the last guidelines
recommend applying antimicrobial stewardship strategies in
patients with sepsis and septic shock, such as de-escalation
and/or discontinuation of antibiotic within the first few days
in response to clinical improvement and infection resolution
and/or lack of evidence of infection (95). Cancer patients
with sepsis and septic shock can be probably managed in the
same way. In this line, we recently published a randomized
clinical trial involving high-risk hematologic patients with febrile
neutropenia without microbiologically documented infection, in
which we demonstrated that empirical antibiotic therapy can
be discontinued after 72 h of apyrexia and clinical recovery
irrespective of the neutrophil count (134). This clinical approach
showed to reduce unnecessary exposure to antimicrobials and to
be safe.
ICU Management
The total number of patients with cancer who need ICU
admission has increased dramatically over time, presently
accounting for up to 15% of all admissions (8, 27–30). Overall
mortality has also decreased and survivors achieve remission
and quality of life after ICU admission, similar to non-ICU
patients (37, 135). Some important changes in the management
of critically ill cancer patients over recent decades have influenced
these improved outcomes. These include the following:
a) Changes in ICU admission policies that may have favored
faster admission of more candidates, leading to early
treatment of organ dysfunction (37, 136).
b) Many so-called classic predictors of mortality (e.g.,
neutropenia, underlying disease, blood transfusion
requirements, and second-line therapies) are no longer
relevant or influence the therapeutic approach less
(32, 137, 138).
c) Improved collaboration between hematologists/oncologists
and intensive care providers (137–140).
d) Improved management of sepsis in neutropenic patients,
including escalation and de-escalation strategies for
antimicrobial therapy, source control (e.g., catheter removal),
and/or conducting surgery if indicated regardless of the
presence of cytopenias (141–143).
e) Using specific therapies for selected patients with
hematological cancers in ICU has also proven to be feasible
and associated with significant survival benefit (144–147).
CURRENT GAPS AND FUTURE RESEARCH
Although much progress has been made in the understanding
and management of sepsis in cancer patients, much is still to
be done.
The increasing number of cancer patients who potentially
require ICU management will necessitate a comprehensive
revision of ICU admission policies. Early recognition of sepsis
based on routine clinical, biochemical, and radiological signs
is still inaccurate in cancer. Future diagnostic strategies must
therefore incorporate newer tests with improved diagnostic
performances, easier non-invasive sampling, and shorter
response time. None of the currently available biomarkers
have demonstrated sufficient sensitivity and/or specificity for
use in clinical practice. Identifying new biomarkers reflecting
host response and/or pathogen invasion may allow better
differentiation of infectious from non-infectious processes and
the early and safe discontinuation of antimicrobial therapy.
In addition, gaining a better understanding of the mutual
interaction between cancer and sepsis, as well as the alterations
in innate and adaptive immune cell functions, could lead to the
development of potential therapeutic interventions. Identifying
biomarkers that can accurately detect and quantify immune
suppression in cancer patients with sepsis will be key to the design
of immunomodulatory therapeutic strategies.
The adequacy of IEAT should be improved in cancer
patients with sepsis, and efforts should be made to ensure
adherence to current guidelines, with adaptation to local
epidemiology where necessary. Studies should also continue to
clarify the role of new antibiotics, such as ceftolozane/tazobactam
and ceftazidime/avibactam, in cancer patients with sepsis,
particularly when used empirically. Other novel antibiotics

























TABLE 3 | Summary of the main clinical and microbiological characteristics of the published case series and case reports on the use of ceftazidime/avibactam and ceftolozane/tazobactam in high-risk hematologic
cancer patients.
References Study design Number of patients Microorganisms
mechanisms of
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receiving other active
antibiotics











(2), and/or colistin (2)
25% with C/A vs. 52% with
other active agents
None/None All treatment regiments were used as
targeted therapy
77.4% were neutropenic
The number of death events were too
small to detect significant differences
Metafuni et al.
(121)
Case series of patients
presenting with persistent
sepsis or septic shock
3 Carbapenemase-producing
K. pneumoniae (n = 2)
MDR-P. aeruginosa (n = 1)
Bacteremia 100% Meropenem (2),
tigecyclin (3), colisitn (2)
33% None/None All treatment regiments were used as
targeted therapy
All patients were neutropenic
Hobson et al.
(122)




Bacteremia Aztreonam (ATM) 0 None/None The patient was neutropenic





Retrospective case series 6 patients received 7
cycles of C/T
MDR-P. aeruginosa Bacteremia (3),
Pneumonia (3), SSTI
(1)
None 0 1 case/1 case Four patients (66.6%) were
neutropenic and two (33.3%) were
HSCT recipients










19 C/T vs. 38 other
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UTI (2), SSTI (1)
42% Amikacin +
levofloxacin (2), amikacin
(4), colistin (1), and
fosfomycin (1)
5.3% with C/T vs. 28.9%
with other active agents
3 cases/None C/T was used empirically in 3 cases,
and as targeted




Case report of a pediatric
patient
1 MDR-P. aeruginosa Bacteremia Tobramycin and
ciprofloxacin
0 None/1 The patient was neutropenic
The MIC to C/T increased from to 6
to 8µg/mL
So et al. (119) Case report 1 MDR-P. aeruginosa Bacteremia Tobramycin 0 None/1 The patient was neutropenic
Bacteremia cleared with the
combination of a
pharmacodynamically driven dose of
C/T and tobramycin with
resultant synergy
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displaying activity againstMDR-GNB are currently under clinical
evaluation (e.g., imipenem/relabactam, plazomicin, cefiderocol,
meropenem/vaborbactam, and eravacycline), and given time,
these may improve the antibiotic armamentarium.
Finally, combining knowledge of more rigorous and
thorough patient stratification and selection, strategic and
careful long-term monitoring of immune function, and targeted
immunomodulatory treatment could optimize clinical benefits
for surviving initial sepsis.
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